Business Context and Reporting Period
This Form 8-K is filed by Emerald Bioscience, Inc. (not Skye Bioscience, Inc.) for the reporting period of August 23, 2019. The filing discloses a material definitive agreement entered into by EMBI Australia Pty Ltd, a wholly owned subsidiary of the registrant.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is an expected payment of approximately $65,840 AUD in professional fees and pass-through costs related to the new agreement.
Material Changes
The primary material change is the execution of a Start-Up Agreement with Novotech (Australia) Pty Limited. This agreement facilitates the launch of the company's first in-human studies for its lead drug candidate, NB1111, targeting healthy volunteers and patients with glaucoma.
Outlook and Management Commentary
- Clinical Trial Launch: The agreement supports the initiation of clinical trials for NB1111.
- Future Agreements: The company and Novotech have agreed to negotiate terms for a Master Services Agreement and Project Agreement to cover all anticipated services for the clinical trial.
- Confidentiality: Certain portions of the attached Start-Up Agreement were redacted as they are deemed not material but competitively harmful if disclosed.
Investor Verification Checklist
- Verify the identity of the registrant as Emerald Bioscience, Inc., noting the discrepancy with the requested company name (Skye Bioscience, Inc.).
- Confirm the status and timeline of the NB1111 clinical trial in Australia.
- Monitor the negotiation progress of the Master Services Agreement and Project Agreement with Novotech.
- Review the attached Exhibit 10.1 for the full terms of the Start-Up Agreement, noting redacted confidential sections.